Emerging Roles of SKP2 in Cancer Drug Resistance
More than half of all cancer patients receive chemotherapy, however, some of them easily acquire drug resistance. Resistance to chemotherapy has become a massive obstacle to achieve high rates of pathological complete response during cancer therapy. S-phase kinase-associated protein 2 (Skp2), as an...
Main Authors: | Ting Wu, Xinsheng Gu, Hongmei Cui |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/5/1147 |
Similar Items
-
Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2
by: Shi-Bing Zhang, et al.
Published: (2022-08-01) -
The SKP2‐p27 axis defines susceptibility to cell death upon CHK1 inhibition
by: Michael Lohmüller, et al.
Published: (2022-08-01) -
Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis
by: Ying Yang, et al.
Published: (2019-04-01) -
The expression and meaning of Skp2, p27 proteins in Mucosa-associated lymphoid tissue lymphoma of ocular adnexal
by: Hong Lin, et al.
Published: (2015-09-01) -
Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib
by: Chen X, et al.
Published: (2020-06-01)